IL-23 Inhibitors for Active Crohn's Disease
Part of Digestive system clinical trials.
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Confirmed Crohn's disease diagnosis with active inflammation shown by endoscopy, imaging, or blood/stool tests
- Planning to start an IL-23 inhibitor (guselkumab or risankizumab) as your next treatment
- Never previously taken an IL-23 inhibitor
- No active infection, tuberculosis, or hepatitis B/C
- Not pregnant, not breastfeeding, and willing to use contraception during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
This trial tests a new antibody drug (IL-23 inhibitor) for people with Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective. You may be able to join if you have moderate to severe disease and have not had certain bowel surgeries or infections.
This study looks at how safe and effective a new type of medicine, called IL-23 inhibitors, is for people with ulcerative colitis or Crohn's disease. If you're starting this treatment for the first time, this study may help us learn more about how well it works.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.